Filing Details

Accession Number:
0000899243-18-000628
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-01-05 20:00:27
Reporting Period:
2018-01-03
Accepted Time:
2018-01-05 20:00:27
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1285819 Omeros Corp OMER Pharmaceutical Preparations (2834) 911663741
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1529087 A Michael Jacobsen 201 Elliott Avenue West
Seattle WA 98119
Vp Finance And Cao No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-01-03 1,020 $9.37 8,520 No 4 M Direct
Common Stock Disposition 2018-01-03 1,020 $22.45 7,500 No 4 S Direct
Common Stock Acquisiton 2018-01-04 1,000 $9.37 8,500 No 4 M Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2018-01-03 1,020 $0.00 1,020 $9.37
Common Stock Stock Option (Right to Buy) Disposition 2018-01-04 1,000 $0.00 1,000 $9.37
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
58,980 2023-09-24 No 4 M Direct
57,980 2023-09-24 No 4 M Direct
Footnotes
  1. Open market sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2017, at which time the trading schedule, including sale periods, price and the number of shares to be sold, was established in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
  2. 25% of the total number of shares subject to this option vested on September 3, 2014, which was the 12-month anniversary of the grant date, and the remaining shares subject to the option vest and become exercisable in equal monthly installments over the 36 months following the initial vesting date.
  3. On January 4, 2018, the reporting person paid the exercise price and exercised options to purchase 1,000 shares of the company's common stock. These shares have not been sold and are held for the account of the reporting person. The options exercised in this transaction have the same vesting terms described in footnote 2.